NSD2 and acute lymphoblastic leukemia: Furthermore, gain-of-function mutations in NSD2 in acute lymphoblastic leukemia (ALL) and several solid tumors enhances methyltransferase activity, thereby driving tumorigenesis [18,19,20,21].